Can Thiết Bị Hỗ Trợ Được Kiểm Soát Tốt: Những Thách Thức và Giải Pháp Từ Nền Tảng Khoa Học

Molderings GJ, Haenisch B, Bogdanow M et al (2013) Familial occurrence of systemic mast cell activation disease. PLoS ONE 8:e76241 Lyons JJ, Yu X, Hughes JD et al (2016) Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 48:1564–1569 Lazaridis N, Germanidis G (2018) Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol 31:171–187 Sido B, Dumoulin FL, Homann J et al (2014) Chirurgische Eingriffe an Patienten mit Mastzellüberaktivitätserkrankung – Operationsrelevante Aspekte am Beispiel einer Cholezystektomie. Chirurg 85:327–333 Molderings GJ, Brettner S, Homann J et al (2011) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 4:10 Afrin LB, Butterfield JH, Raithel M et al (2016) Often seen, rarely recognized: mast cell activation disease—a guide to diagnosis and therapeutic options. Ann Med 48:190–201 Molderings GJ (2016) Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features. Transl Res 16(174):86–97 Frieling T, Meis K, Kolck UW et al (2011) Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol 49:191–194 Lee KN, Lee OY (2016) The role of mast cells in irritable bowel syndrome. Gastroenterol Res Pract 2016:2031480 Zhang L, Song J, Hou X (2016) Mast cells and irritable bowel syndrome: from the bench to the bedside. J Neurogastroenterol Motil 22:181–192 Tsilioni I, Russell IJ, Stewart JM et al (2016) Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 356:664–672 Mastrangelo F, Frydas I, Ronconi G et al (2018) Low-grade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37. J Biol Regul Homeost Agents 32:195–198 Molderings GJ, Homann J, Brettner S et al (2014) Systemische Mastzellaktivierungserkrankung: Ein praxisorientierter Leitfaden zu Diagnostik und Therapie. Dtsch Med Wochenschr 139:1523–1534 Afrin LB, Molderings GJ (2014) A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol 3:1–17 Seidel H, Molderings GJ, Oldenburg J et al (2011) Bleeding diathesis in patients with mast cell activation disease. Thromb Haemost 106:987–989 Vysniauskaite M, Hertfelder H‑J, Oldenburg J et al (2015) Determination of plasma heparin level improves identification of systemic mast cell activation disease. PLoS ONE 10:e124912 Valent P, Akin C, Arock M et al (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157:215–225 Molderings GJ (2015) The genetic basis of mast cell activation disease—looking through a glass darkly. Crit Rev Oncol Hematol 93:75–89 Afrin LB, Molderings GJ (2014) A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol 3:1–17 Yousefi OS, Wilhelm T, Maschke-Neuß K et al (2013) The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions. Cell Commun Signal 11:13 Henzen C (2011) Nebennierenrindeninsuffizienz – Abklärung und Therapie im klinischen Alltag. Ther Umsch 68:337–343 Zhang T, Che D, Liu R et al (2017) Typical antimicrobials induce mast cell degranulation and anaphylactoid reactions via MRGPRX2 and its murine homologue MRGPRB2. Eur J Immunol 47:1949–1958 Navinés-Ferrer A, Serrano-Candelas E, Lafuente A et al (2018) MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep 8:11628 Shtessel M et al (2018) In vivo mast cell activation by the MRGPRX2 receptor ligands. J Allergy Clin Immunol 141:AB35 Abajian M, Młynek A, Maurer M (2012) Physical urticaria. Curr Allergy Asthma Rep 12:281–287 Afrin LB (2016) Never bet against Occam: Mast cell activation disease and the modern epidemics of chronic illness and medical complexity. Sisters Media LLC, Bethesda Jennings S, Russell N, Jennings B et al (2014) The mastocytosis society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract 2:70–76 Moreno-Ancillo A, Gil-Adrados AC, Domínguez-Noche C et al (2013) Bleeding and shock in a 44-year-old woman with systemic mastocytosis. J Investig Allergol Clin Immunol 23:517–518 Sucker C, Mansmann G, Steiner S et al (2008) Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis. Clin Appl Thromb Hemost 14:360–364 Ahmed M, Kesavan M, Jilani BN et al (2016) Systemic mastocytosis as an unconventional cause of variceal bleeding: think outside the box. Cureus 8:e629 Horrow JC (1985) Protamine: a review of its toxicity. Anesth Analg 64:348–361 Hoffmann K, Xifró RA, Hartweg JL et al (2013) Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells. Eur J Pharmacol 700:152–158 Alfter K, von Kügelgen I, Haenisch B et al (2009) New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int 29:181–186 Wirz S, Molderings GJ (2017) A practical guide for treatment of pain in patients with systemic mast cell activation disease. Pain Physician 20:E849–E861 Zhou X, Xiao Z, Xu Y et al (2017) Electrophysiological and pharmacological analyses of Nav1.9 voltage-gated sodium channel by establishing a heterologous expression system. Front Pharmacol 8:852 Lee WM (2017) Acetaminophen (APAP) hepatotoxicity—Isn’t it time for APAP to go away? J Hepatol 67:1324–1331 Afrin LB (2016) Mast cell disease: beyond allergy and mastocytosis. Transl Res 174:1–4